CLOs on the Move

Merrimack

www.merrimack.com

 
At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.merrimack.com
  • One Kendall Square Building 700, Suite B7201
    Cambridge, MA USA 02139
  • Phone: 617.441.1000

Executives

Name Title Contact Details

Similar Companies

uniPHARM Wholesale Drugs

uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Novartis

Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.

Immune Tolerance Network

Immune Tolerance Network is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healix

Healix Ltd is a Sugar Land, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health & Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.